Cargando…

Evolution of clinical trials in multiple sclerosis

Clinical trials have advanced the treatment of multiple sclerosis (MS) by demonstrating the safety and efficacy of disease-modifying therapies (DMTs). This review discusses major changes to MS clinical trials in the era of DMTs. As treatment options for MS continue to increase, patients in modern MS...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Yinan, Salter, Amber, Wallström, Erik, Cutter, Gary, Stüve, Olaf
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6391540/ https://www.ncbi.nlm.nih.gov/pubmed/30833985 http://dx.doi.org/10.1177/1756286419826547

Ejemplares similares

Clinical trials in multiple sclerosis: milestones
por: Zhang, Yinan, et al.
Publicado: (2018)

Clinical trials in multiple sclerosis: potential future trial designs
por: Manouchehri, Navid, et al.
Publicado: (2019)

Disease-modifying therapy prescription patterns in people with multiple sclerosis by age
por: Zhang, Yinan, et al.
Publicado: (2021)

Aging and efficacy of disease-modifying therapies in multiple sclerosis: a meta-analysis of clinical trials
por: Zhang, Yinan, et al.
Publicado: (2020)

The incidence and prevalence of psychiatric disorders in multiple sclerosis: A systematic review
por: Marrie, Ruth Ann, et al.
Publicado: (2015)

A systematic review of the incidence and prevalence of autoimmune disease in multiple sclerosis
por: Marrie, Ruth Ann, et al.
Publicado: (2015)

A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: Overview
por: Marrie, Ruth Ann, et al.
Publicado: (2015)

A systematic review of the incidence and prevalence of cancer in multiple sclerosis
por: Marrie, Ruth Ann, et al.
Publicado: (2015)

Improving the efficiency of clinical trials in multiple sclerosis
por: Marrie, Ruth Ann, et al.
Publicado: (2023)

A systematic review of the incidence and prevalence of sleep disorders and seizure disorders in multiple sclerosis
por: Marrie, Ruth Ann, et al.
Publicado: (2015)

Uptake and Attitudes About Immunizations in People With Multiple Sclerosis
por: Marrie, Ruth Ann, et al.
Publicado: (2021)

A systematic review of the incidence and prevalence of cardiac, cerebrovascular, and peripheral vascular disease in multiple sclerosis
por: Marrie, Ruth Ann, et al.
Publicado: (2015)

Attitudes of people with multiple sclerosis toward brain donation
por: Marrie, Ruth Ann, et al.
Publicado: (2023)

Spotlight on daclizumab: its potential in the treatment of multiple sclerosis
por: Milo, Ron, et al.
Publicado: (2016)

Attitudes toward coronavirus disease 2019 vaccination in people with multiple sclerosis
por: Marrie, Ruth Ann, et al.
Publicado: (2022)

The incidence and prevalence of comorbid gastrointestinal, musculoskeletal, ocular, pulmonary, and renal disorders in multiple sclerosis: A systematic review
por: Marrie, Ruth Ann, et al.
Publicado: (2015)

Comparing the MSIS-29 and the Health Utilities Index Mark III in Multiple Sclerosis
por: Marrie, Ruth Ann, et al.
Publicado: (2021)

Preferred Sources of Health Information in Persons With Multiple Sclerosis: Degree of Trust and Information Sought
por: Marrie, Ruth Ann, et al.
Publicado: (2013)

The sequential natalizumab – alemtuzumab therapy in patients with relapsing forms of multiple sclerosis (SUPPRESS) trial – Part I: Rationale and objectives
por: Hussain, Rehana Z, et al.
Publicado: (2022)

Intractable and highly active relapsing multiple sclerosis – role of alemtuzumab
por: Dubey, Divyanshu, et al.
Publicado: (2015)

Health Literacy Association With Health Behaviors and Health Care Utilization in Multiple Sclerosis: A Cross-Sectional Study
por: Marrie, Ruth Ann, et al.
Publicado: (2014)

Developing a crosswalk between the RAND-12 and the health utilities index for multiple sclerosis
por: Marrie, Ruth Ann, et al.
Publicado: (2019)

Prevalence and characteristics of tremor in the NARCOMS multiple sclerosis registry: a cross-sectional survey
por: Rinker, John R, et al.
Publicado: (2015)

Physical and Mental Health–Related Quality of Life Trajectories Among People With Multiple Sclerosis
por: O'Mahony, Julia, et al.
Publicado: (2022)

The role of the complement system in Multiple Sclerosis: A review
por: Saez-Calveras, Nil, et al.
Publicado: (2022)

Severity and worsening of fatigue among individuals with multiple sclerosis
por: Salter, Amber, et al.
Publicado: (2023)

Critical appraisal of the role of fingolimod in the treatment of multiple sclerosis
por: Warnke, Clemens, et al.
Publicado: (2011)

Review of teriflunomide and its potential in the treatment of multiple sclerosis
por: Warnke, Clemens, et al.
Publicado: (2009)

Identification of targets and new developments in the treatment of multiple sclerosis – focus on cladribine
por: Warnke, Clemens, et al.
Publicado: (2010)

Sources of Cannabis Information and Medical Guidance for Neurologic Use: NARCOMS Survey of People Living With Multiple Sclerosis
por: Salter, Amber, et al.
Publicado: (2022)

Targeting “bad” B cells in multiple sclerosis: Could laquinimod be part of the armamentarium?
por: Forsthuber, Thomas G., et al.
Publicado: (2016)

Editorial: Animal models of multiple sclerosis: can they advance future therapies?
por: DeSilva, Tara Maria, et al.
Publicado: (2023)

Ectopic Lymphoid Follicles in Multiple Sclerosis: Centers for Disease Control?
por: Negron, Austin, et al.
Publicado: (2020)

A propensity-matched comparison of long-term disability worsening in patients with multiple sclerosis treated with dimethyl fumarate or fingolimod
por: Salter, Amber, et al.
Publicado: (2021)

Should ocrelizumab be used in non-active primary progressive multiple sclerosis? Time for a re-assessment
por: Manouchehri, Navid, et al.
Publicado: (2021)

T cell responses to COVID-19 infection and vaccination in patients with multiple sclerosis receiving disease-modifying therapy
por: Reder, Anthony T, et al.
Publicado: (2022)

Cognitive Decline in Older People with Multiple Sclerosis—A Narrative Review of the Literature
por: Chiang, Hsueh-Sheng, et al.
Publicado: (2022)

National estimates of self-reported sitting time in adults with multiple sclerosis
por: Sasaki, JE, et al.
Publicado: (2018)

Defining the clinical course of multiple sclerosis: The 2013 revisions
por: Lublin, Fred D., et al.
Publicado: (2014)

The validity of animal models to explore the pathogenic role of the complement system in multiple sclerosis: A review
por: Saez-Calveras, Nil, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_slrvdjn6gaaje1s0fcogd6buh2